Vaccine maker warns Dengue vaccine can cause severe dengue

[MindWars]

Vaccine Maker Warns Dengue Vaccine Can Cause Severe Dengue
Vaccine manufacturer Sanofi Pasteur announced Wednesday that a dengue vaccine already distributed to hundreds of thousands of schoolchildren could instead cause more severe cases of the disease in people who were not already infected.
------------------------------------------------------------------------------------------

View attachment 163659

Vaccinated Filipino youth now at risk of getting severe dengue
----------------------------------------------------------------------------------------------------------------


But hey keep getting those vaccines because people dying and getting sick is just a freaking conspiracy right people just make that shit up. LOL

Sanofi updates information on dengue vaccine

• New analysis of long-term Dengvaxia® data found differences in vaccine performance based on prior dengue infection
• Company will ask regulators to update product label to reflect new information

PARIS, FRANCE – November 29, 2017 – Sanofi will ask health authorities to update information provided to physicians and patients on its dengue vaccine Dengvaxia® in countries where it is approved. The request is based on a new analysis of long-term clinical trial data, which found differences in vaccine performance based on prior dengue infection.
http://mediaroom.sanofi.com/sanofi-updates-information-on-dengue-vaccine/

 

[Peach]

Thank you for this informative post.

 

[waltky]

Dengue vaccine could pose health risks...

Philippines launches probe into dengue vaccine scare
4 Dec.`17 - The Philippines has launched an investigation into the immunisation of 730,000 children with a dengue vaccine that could pose health risks.

Last week French drug company Sanofi announced its vaccine could worsen the potentially deadly disease in people not previously infected. The public immunisation programme was suspended on Friday. Dengue fever affects more than 400 million people each year around the world. The mosquito-borne disease is a leading cause of serious illness and death among children in some Asian and Latin American countries, according to the World Health Organization (WHO). Sanofi's Dengvaxia is the first-ever approved dengue vaccine. In addition to the Philippines, the company said the vaccine was registered in Argentina, Australia, Bangladesh, Bolivia, Brazil, Cambodia, Costa Rica, El Salvador, Guatemala, Honduras, Indonesia, Malaysia, Mexico, Paraguay, Peru, Singapore, Thailand and Venezuela. The vaccine has also been used in a public immunisation programme in Brazil which, combined with the Philippines scheme, has to date provided around one million people at least one dose of drug.

Dengue is a potentially deadly mosquito-borne disease​

Sanofi said in a press conference on Monday that there had been no reported deaths related to its dengue vaccine in the Philippines. "As far as we know, as far as we are made aware, there are no reported deaths that are related to dengue vaccination," the company's medical director, Ruby Dizon, told reporters on Monday. "Of course, rest assured, monitoring is continuing, we are working with the department of health (DOH), in collaboration, to make sure this is maintained. "Philippine presidential spokesperson Harry Roque said on Monday that "people should not panic over the dengue vaccine" as the government was looking into the matter. Dengue is a viral infection which causes a severe, flu-like illness that can be fatal if it develops into its most serious form. The global incidence of dengue has risen dramatically in recent decades, according to the WHO, putting about half the world's population at risk of the disease.

WHO recommendation

Sanofi said last week that a new long-term study had shown that while the Dengvaxia vaccine worked with people who had prior infection, it posed a risk for those who hadn't. "For those not previously infected by dengue virus, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection," the company said in a statement. The French drug maker said it would ask health authorities to update the information given to doctors and patients working with the vaccine. In its latest advice on the vaccine, the WHO recommended that Dengvaxia should only be administered to "subjects that are known to have been infected with dengue prior to vaccination," pending a full review of the study.

Philippines to probe dengue vaccine scare

 

[MindWars]

THIS GUY IS REALLY WORTH LISTENING TO.

 

[MindWars]

Something more people should think about and they don't.

 

[waltky]

Deaths of 3 Children Linked to Dengue Vaccine In Philippines...

In Philippines, Deaths of 3 Children Linked to Dengue Vaccine
February 03, 2018 — The Philippines said Friday the anti-dengue vaccine Dengvaxia may be connected to three deaths in the country, according to a government-ordered inquiry, and that the drug is not ready for mass immunization.

Sanofi revealed in November that Dengvaxia, the world’s first dengue vaccine, might increase the risk of severe disease in people who had never been exposed to the virus. The news prompted an uproar in the Philippines, where more than 800,000 school-age children were vaccinated in 2016. “We sympathize with all the families who have suffered the loss of a child. Sanofi Pasteur’s mission is to reduce or eliminate suffering for millions around the world through vaccination, including in the Philippines,” a spokesman for the French drugmaker said in an emailed statement.

Protesters display slogans during a rally against the controversial immunization of more than 700,000 Filipino children with the anti-dengue vaccine Dengvaxia in Manila, Philippines, Dec. 18, 2017. The controversial vaccine, manufactured by Sanofi Pasteur was recently put on hold by the Philippines after new study findings showed it posed risks of severe cases in people without previous infection. The controversy has prompted the Philippine Senate to conduct an investigation.​

The Philippine Health Ministry halted Dengvaxia immunizations in November. It formed a 10-member panel of experts to determine if the drug was directly connected to the deaths of 14 children after they were given the vaccine. It found it may have been connected to the deaths of three. “Three cases were found to have causal association. They died of dengue even (though) they were given Dengvaxia. Two of them may have died because of vaccine failure,” Health Undersecretary Enrique Domingo told a news conference. “These findings strengthen the decision of the Department of Health to stop the vaccine. It has failed in some children. Dengvaxia is not ready for mass vaccinations, and we would need three to five more years to watch and monitor if there would be other adverse reactions from the vaccine.”

Mosquito-borne dengue is the world’s fastest-growing infectious disease, afflicting up to 100 million people worldwide, causing half a million life-threatening infections and killing about 20,000 people, mostly children, each year. Domingo said the panel’s findings would be shared with the justice department, which is considering cases against those responsible for the mass immunization program. Pediatrician and panel member Juliet Sio-Aguilar, from the University of the Philippines-Philippine General Hospital (UP-PGH), said the team was recommending further studies because it was difficult to directly connect the three deaths to Dengvaxia. No vaccine has a 100 percent success rate, she said. The dengue death rate in the Philippines was 60 times higher than global rate, Sio-Aguilar said.

Department of Health Undersecretary Dr. Rolando Enrique Domingo, right, and Philippine General Hospital Director Dr. Gerardo Legaspi, attend a press conference at the Department of Health office in Manila, Philippines​

Sanofi said Saturday the UP-PGH’s findings confirmed there is currently no evidence directly linking the Dengvaxia vaccine to any of the 14 deaths. “In Dengvaxia clinical trials conducted over more than a decade and the over 1 million doses of the vaccine administered, no deaths related to the vaccine have been reported to us,” the company said in a statement. The Philippines spent 3.5 billion pesos ($68 million) on the Dengvaxia program to reduce the 200,000 dengue cases reported every year. Sanofi said clinical evidence confirms dengue vaccination in the Philippines will provide a net reduction in dengue disease, including severe dengue. The Philippines has fined Sanofi a symbolic $2,000, citing violations in product registration and marketing.

In Philippines, Deaths of 3 Children Linked to Dengue Vaccine

 

[MindWars]

Deaths of 3 Children Linked to Dengue Vaccine In Philippines...

In Philippines, Deaths of 3 Children Linked to Dengue Vaccine
February 03, 2018 — The Philippines said Friday the anti-dengue vaccine Dengvaxia may be connected to three deaths in the country, according to a government-ordered inquiry, and that the drug is not ready for mass immunization.

Sanofi revealed in November that Dengvaxia, the world’s first dengue vaccine, might increase the risk of severe disease in people who had never been exposed to the virus. The news prompted an uproar in the Philippines, where more than 800,000 school-age children were vaccinated in 2016. “We sympathize with all the families who have suffered the loss of a child. Sanofi Pasteur’s mission is to reduce or eliminate suffering for millions around the world through vaccination, including in the Philippines,” a spokesman for the French drugmaker said in an emailed statement.

Protesters display slogans during a rally against the controversial immunization of more than 700,000 Filipino children with the anti-dengue vaccine Dengvaxia in Manila, Philippines, Dec. 18, 2017. The controversial vaccine, manufactured by Sanofi Pasteur was recently put on hold by the Philippines after new study findings showed it posed risks of severe cases in people without previous infection. The controversy has prompted the Philippine Senate to conduct an investigation.​

The Philippine Health Ministry halted Dengvaxia immunizations in November. It formed a 10-member panel of experts to determine if the drug was directly connected to the deaths of 14 children after they were given the vaccine. It found it may have been connected to the deaths of three. “Three cases were found to have causal association. They died of dengue even (though) they were given Dengvaxia. Two of them may have died because of vaccine failure,” Health Undersecretary Enrique Domingo told a news conference. “These findings strengthen the decision of the Department of Health to stop the vaccine. It has failed in some children. Dengvaxia is not ready for mass vaccinations, and we would need three to five more years to watch and monitor if there would be other adverse reactions from the vaccine.”

Mosquito-borne dengue is the world’s fastest-growing infectious disease, afflicting up to 100 million people worldwide, causing half a million life-threatening infections and killing about 20,000 people, mostly children, each year. Domingo said the panel’s findings would be shared with the justice department, which is considering cases against those responsible for the mass immunization program. Pediatrician and panel member Juliet Sio-Aguilar, from the University of the Philippines-Philippine General Hospital (UP-PGH), said the team was recommending further studies because it was difficult to directly connect the three deaths to Dengvaxia. No vaccine has a 100 percent success rate, she said. The dengue death rate in the Philippines was 60 times higher than global rate, Sio-Aguilar said.

Department of Health Undersecretary Dr. Rolando Enrique Domingo, right, and Philippine General Hospital Director Dr. Gerardo Legaspi, attend a press conference at the Department of Health office in Manila, Philippines​

Sanofi said Saturday the UP-PGH’s findings confirmed there is currently no evidence directly linking the Dengvaxia vaccine to any of the 14 deaths. “In Dengvaxia clinical trials conducted over more than a decade and the over 1 million doses of the vaccine administered, no deaths related to the vaccine have been reported to us,” the company said in a statement. The Philippines spent 3.5 billion pesos ($68 million) on the Dengvaxia program to reduce the 200,000 dengue cases reported every year. Sanofi said clinical evidence confirms dengue vaccination in the Philippines will provide a net reduction in dengue disease, including severe dengue. The Philippines has fined Sanofi a symbolic $2,000, citing violations in product registration and marketing.

In Philippines, Deaths of 3 Children Linked to Dengue Vaccine

Thanks for always stopping by Walt

 

[waltky]

Yer welcome.

 

[MindWars]

2-month old Dies 48 hours After 8 Vaccines: Owen's Mom Speaks Out

 

[MindWars]

Oh imagine that, this just out today :

Flu Vaccine Less Effective Than Earlier Estimates